Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Teva Pharmaceutical Industries Limited    TEVA   IL0006290147

SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Mylan N.V.(NASDAQ:MYL)’s Generic Version Of Teva Pharmaceutical Industries Ltd (ADR)(NYSE:TEVA)’s Copaxone Approved

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 04:16pm CEST

A generic version of Teva Pharmaceutical Industries Ltd (ADR)(NYSE:TEVA)’s Copaxone which has been developed by Mylan N.V.(NASDAQ:MYL) has been approved by the U.S. Food and Drug Administration. Copaxone is a blockbuster drug that is used in the treatment of multiple sclerosis.

The approval of the copaxone generic was a surprise to both Teva and Mylan since they had not been expecting it to happen so soon. This came a day after the FDA announced that measures would be introduced with a view to speeding up the approval of generics of complex drugs such as copaxone so that they can get to the market faster and assist in addressing the increasing cost of drugs.

Blockbuster drug

Copaxone is not only the leading therapy for multiple sclerosis in the world but is also the best-selling drug ever developed by Teva. Last year it generated revenues amounting to over $4 billion for the pharmaceutical giant headquartered in Tel Aviv, Israel.

According to Teva, the launch of the generic version of Copaxone was being done prior to the resolution of a couple of patent appeals. This implies that Mylan would end up paying significant damages in the event that Teva prevailed.

Two varying doses of the generic were approved by the FDA and this include the 40 mg dose and the 20mg dose. In this year’s second quarter, over 85% of the Copaxone prescriptions were made for the 40 mg dose.

Loss for Teva

According to analysts the approval amounted to a win for Mylan and a loss for Teva and projected that this would be reflected in both this year’s and next year’s earnings. Mylan’s first generic-version application for Copaxone was filed in 2009.

“Bottom line, this is incrementally positive for Mylan while for Teva both a negative surprise and a cash flow hit to 2018,” wrote Randall Stanicky, an RBC analyst, in a client note.

Two months ago U.S. Congress launched an investigation on drug pricing and Teva was among the pharmaceutical companies contacted over the cost of its multiple sclerosis drug. In 2017 the annual cost for the 20 mg dose of Copaxone is over $90,000 despite the fact that it was unveiled in 1996 and back then it used to cost approximately $8,000.

On Wednesday shares of Mylan N.V. rose by 16.20% to close the day at $37.80.

The post Mylan N.V.(NASDAQ:MYL)’s Generic Version Of Teva Pharmaceutical Industries Ltd (ADR)(NYSE:TEVA)’s Copaxone Approved appeared first on Market Exclusive.

© Market Exclusive 2017, source Market Exclusive

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TEVA PHARMACEUTICAL INDUST
10/17 TEVA PHARMACEUTICAL INDUSTRIES LIMIT : DEADLINE ALERT: Lundin Law PC Announces a..
10/17 Amneal, Impax combine to tackle generic drug pricing pressure
10/17 TEVA PHARMACEUTICAL INDUSTRIES LIMIT : TEVA The Law Offices of Vincent Wong Remi..
10/17 TEVA PHARMACEUTICAL INDUSTRIES : "Teva unlikely to remain priced below Mylan"
10/17 TEVA PHARMACEUTICAL INDUSTRIES : Announces Submission of Biologics License Appli..
10/16 TEVA PHARMACEUTICAL INDUSTRIES : "Teva unlikely to remain priced below Mylan"
10/16 TEVA PHARMACEUTICAL INDUSTRIES LIMIT : Khang & Khang LLP Announces Securities Cl..
10/16 TEVA PHARMACEUTICAL INDUSTRIES LIMIT : Levi & Korsinsky, LLP Reminds Shareholder..
10/14 DEADLINE ALERT : Brower Piven Reminds Shareholders of Approaching Deadline in Cl..
10/14 TEVA PHARMACEUTICAL INDUSTRIES LIMIT : SHAREHOLDER REMINDER: Lundin Law PC Annou..
More news
News from SeekingAlpha
10/17 TEVA : The Very Long Bull Case
10/17 ADAMIS PHARMACEUTICALS : Buy The Dip Ahead Of Symjepi Partnership And Launch
10/17 Teva submits U.S. marketing application for migraine med fremanezumab
10/16 TEVA'S ONGOING COMPLICATIONS : Psychology And Generic Drugs
10/16 U.S. court invalidates Allergan's Restasis patents; shares down 5%
Financials ($)
Sales 2017 22 644 M
EBIT 2017 6 282 M
Net income 2017 -
Debt 2017 34 451 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 2,19x
EV / Sales 2018 2,08x
Capitalization 15 055 M
Chart TEVA PHARMACEUTICAL INDUST
Duration : Period :
Teva Pharmaceutical Indust Technical Analysis Chart | TEVA | IL0006290147 | 4-Traders
Technical analysis trends TEVA PHARMACEUTICAL INDUST
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 28,0 $
Spread / Average Target 90%
Managers
NameTitle
Kåre Schultz President & Chief Executive Officer
Sol J. Barer Chairman
Carlo de Notaristefani President & CEO-Global Operations
Michael McClellan Chief Financial Officer
Michael R. Hayden Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
TEVA PHARMACEUTICAL INDUSTRIES LIMITED-59.72%15 055
JOHNSON & JOHNSON18.42%365 346
NOVARTIS13.23%226 956
ROCHE HOLDING LTD.5.20%215 359
PFIZER11.88%214 265
MERCK AND COMPANY7.68%172 751